Phreesia (PHR) Stock Price

Phreesia Price

NYSE·CLOSED
10.73USD+0.12 (+1.12 %)
Market closed

Revenue has compounded at 26.4% per year over the past 8 years to 473.64 M USD. Phreesia's net margin stands at 0.5%, up from -56.0% several years earlier. Analysts set a median price target of 28.56 USD, implying 166.2% above the current price. Of 24 analysts, 23 rate the stock a buy — an overall Buy consensus. The stock trades about 33% above its 52-week low.

Phreesia stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Phreesia over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Phreesia stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Phreesia's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Phreesia Stock Price History
DatePhreesia Price
7/31/202610.73 USD
7/30/202610.61 USD
7/29/202611.05 USD
7/27/202610.77 USD
7/23/20269.80 USD
7/22/202610.01 USD
7/21/202610.60 USD
7/20/202610.68 USD
7/17/202610.71 USD
7/16/202610.89 USD
7/15/202610.76 USD
7/14/202610.74 USD
7/13/202611.10 USD
7/10/202610.72 USD
7/9/202610.82 USD
7/8/202610.64 USD
7/7/202610.95 USD
7/6/202610.79 USD
7/2/202610.94 USD
7/1/202610.72 USD
6/30/202610.29 USD
6/29/20269.91 USD
6/26/202610.07 USD
6/25/20269.13 USD
6/24/20269.59 USD
6/23/20269.15 USD
6/22/20269.06 USD
6/18/20269.45 USD
6/17/20269.50 USD
6/16/20269.30 USD
6/15/20269.27 USD
6/12/20269.02 USD
6/11/20268.93 USD
6/10/20269.20 USD
6/9/20269.29 USD
6/8/20269.34 USD
6/5/20269.42 USD
6/4/20269.89 USD
6/3/20269.67 USD
6/2/202610.22 USD
6/1/202610.30 USD
5/29/20269.43 USD
5/28/20269.59 USD
5/27/20269.06 USD
5/26/20268.90 USD
5/22/20268.85 USD
5/21/20268.69 USD
5/20/20268.73 USD
5/19/20269.17 USD
5/18/20269.08 USD
5/15/20268.77 USD
5/14/20268.77 USD
5/13/20269.19 USD
5/12/20269.61 USD
5/11/20269.57 USD
5/8/202610.17 USD
5/7/20269.83 USD
5/6/20269.53 USD
5/5/20269.65 USD
5/4/20269.67 USD
5/1/20269.67 USD
4/30/20269.21 USD
4/29/20269.37 USD
4/28/20269.42 USD
4/27/20269.62 USD
4/24/20269.54 USD
4/23/20268.91 USD
4/22/20269.32 USD
4/21/20269.36 USD
4/20/20269.43 USD
4/17/20269.17 USD
4/16/20269.17 USD
4/15/20269.06 USD
4/14/20268.60 USD
4/13/20268.56 USD
4/10/20268.06 USD
4/9/20268.09 USD
4/8/20268.75 USD
4/7/20269.06 USD
4/6/20269.15 USD
4/2/20268.37 USD
4/1/20268.40 USD
3/31/20268.38 USD
3/30/202611.41 USD
3/27/202610.98 USD
3/26/202611.65 USD
3/25/202611.28 USD
3/24/202611.28 USD
3/23/202611.80 USD
3/20/202611.86 USD
3/19/202611.77 USD
3/18/202611.20 USD
3/17/202611.19 USD
3/16/202610.99 USD
3/13/202610.97 USD
3/12/202611.00 USD
3/11/202611.34 USD
3/10/202611.75 USD
3/9/202612.06 USD
3/6/202612.05 USD
3/5/202612.08 USD
3/4/202612.63 USD
3/3/202612.37 USD
3/2/202612.27 USD
2/27/202612.33 USD
2/26/202612.33 USD
2/25/202611.83 USD
2/24/202611.66 USD
2/23/202611.70 USD
2/20/202612.71 USD
2/19/202612.58 USD
2/18/202612.10 USD
2/17/202611.83 USD
2/13/202611.95 USD
2/12/202611.86 USD
2/11/202612.50 USD
2/10/202612.41 USD
2/9/202612.22 USD
2/6/202612.20 USD
2/5/202612.59 USD
2/4/202612.83 USD
2/3/202612.78 USD
2/2/202613.21 USD
1/30/202613.43 USD
1/29/202613.95 USD
1/28/202614.66 USD
1/27/202615.19 USD
1/26/202615.72 USD
1/23/202615.84 USD
1/22/202615.80 USD
1/21/202615.62 USD
1/20/202615.73 USD
1/16/202616.39 USD
1/15/202616.45 USD
1/14/202616.11 USD
1/13/202616.58 USD
1/12/202617.14 USD
1/9/202617.23 USD
1/8/202616.90 USD
1/7/202617.52 USD
1/6/202617.24 USD
1/5/202617.12 USD
1/2/202616.30 USD
12/31/202516.92 USD
12/30/202517.03 USD
12/29/202517.00 USD
12/26/202517.02 USD
12/24/202516.81 USD
12/23/202516.78 USD
12/22/202516.47 USD
12/19/202516.55 USD
12/18/202516.41 USD
12/17/202516.30 USD
12/16/202516.35 USD
12/15/202516.70 USD
12/12/202516.25 USD
12/11/202516.04 USD
12/10/202515.78 USD
12/9/202515.43 USD
12/8/202520.12 USD
12/5/202520.29 USD
12/4/202520.55 USD
12/3/202520.38 USD
12/2/202520.15 USD
12/1/202520.01 USD
11/28/202520.49 USD
11/26/202520.53 USD
11/25/202520.62 USD
11/24/202520.28 USD
11/21/202520.05 USD
11/20/202519.05 USD
11/19/202519.19 USD
11/18/202519.60 USD
11/17/202520.60 USD
11/14/202521.77 USD
11/13/202522.53 USD
11/12/202523.15 USD
11/11/202522.75 USD
11/10/202522.62 USD
11/7/202522.02 USD
11/6/202522.27 USD
11/5/202522.67 USD
11/4/202522.54 USD
11/3/202522.73 USD
10/31/202522.64 USD
10/30/202522.66 USD
10/29/202523.22 USD
10/28/202523.41 USD
10/27/202523.47 USD
10/24/202523.48 USD
10/23/202523.49 USD
10/22/202523.45 USD
10/21/202523.11 USD
10/20/202522.94 USD
10/17/202522.29 USD
10/16/202522.75 USD
10/15/202522.93 USD
10/14/202522.90 USD
10/13/202522.24 USD
10/10/202522.26 USD
10/9/202523.84 USD
10/8/202523.25 USD
10/7/202523.41 USD
10/6/202523.48 USD
10/3/202523.27 USD
10/2/202522.84 USD
10/1/202522.45 USD
9/30/202523.52 USD
9/29/202523.55 USD
9/26/202523.62 USD
9/25/202523.45 USD
9/24/202523.66 USD
9/23/202523.80 USD
9/22/202524.74 USD
9/19/202523.87 USD
9/18/202524.19 USD
9/17/202523.28 USD
9/16/202523.50 USD
9/15/202523.38 USD
9/12/202524.19 USD
9/11/202525.48 USD
9/10/202525.34 USD
9/9/202526.55 USD
9/8/202526.78 USD
9/5/202528.13 USD
9/4/202531.21 USD
9/3/202530.44 USD
9/2/202531.48 USD
8/29/202531.66 USD
8/28/202532.55 USD
8/27/202531.99 USD
8/26/202530.80 USD
8/25/202530.39 USD
8/22/202529.75 USD
8/21/202528.76 USD
8/20/202527.70 USD
8/19/202528.25 USD
8/18/202529.10 USD
8/15/202528.70 USD
8/14/202528.01 USD
8/13/202528.65 USD
8/12/202527.85 USD
8/11/202527.13 USD
8/8/202527.01 USD
8/7/202526.84 USD
8/6/202527.11 USD
8/5/202527.10 USD
Access this data via the Eulerpool API

Phreesia Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
354.45 M USD
-136.48 M USD
-136.89 M USD
Jan 1, 2025
417.47 M USD
-58.10 M USD
-58.53 M USD
Jan 1, 2026
473.64 M USD
-4.16 M USD
2.31 M USD
Jan 1, 2027 (e)
515.15 M USD
235.24 M USD
24.18 M USD
Jan 1, 2028 (e)
538.45 M USD
245.88 M USD
39.05 M USD
Jan 1, 2029 (e)
560.08 M USD
255.75 M USD
46.65 M USD
Jan 1, 2030 (e)
539.20 M USD
246.22 M USD
55.47 M USD
Jan 1, 2031 (e)
553.00 M USD
252.52 M USD
59.69 M USD

Phreesia Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 12:59 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2018201920202021202220232024202520262027e2028e2029e2030e2031e
79.0099.00124.00148.00213.00280.00356.00419.00480.00515.00538.00560.00539.00553.00
25.3225.2519.3543.9231.4627.1417.7014.567.294.474.09-3.752.60
63.2962.6364.5264.8661.5061.0765.1767.7867.9267.9267.9267.9267.9267.92
50.0062.0080.0096.00131.00171.00232.00284.00326.00349.77365.39380.33366.07375.58
-15.00-9.00-19.00-25.00-116.00-176.00-136.00-58.00-4.00235.00245.00255.00246.00252.00
-18.99-9.09-15.32-16.89-54.46-62.86-38.20-13.84-0.8345.6345.5445.5445.6445.57
-18.00-15.00-20.00-27.00-118.00-176.00-136.00-58.002.0024.0039.0046.0055.0059.00
-16.6733.3335.00337.0449.15-22.73-57.35-103.451,100.0062.5017.9519.577.27
28.1935.7938.5151.0252.6155.2557.8961.4962.0462.0462.0462.0462.0462.04
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Phreesia generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Phreesia retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Phreesia's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Phreesia has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Phreesia's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Phreesia stock margins

The Phreesia margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Phreesia. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Phreesia.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
62.47 %
-55.38 %
-55.98 %
Jan 1, 2023
61.10 %
-62.85 %
-62.71 %
Jan 1, 2024
65.54 %
-38.50 %
-38.62 %
Jan 1, 2025
68.24 %
-13.92 %
-14.02 %
Jan 1, 2026
68.93 %
-0.88 %
0.49 %
Jan 1, 2027 (e)
68.93 %
45.66 %
4.69 %
Jan 1, 2028 (e)
68.93 %
45.66 %
7.25 %
Jan 1, 2029 (e)
68.93 %
45.66 %
8.33 %

Phreesia Stock Revenue, EBIT, Earnings per Share

The Phreesia earnings per share therefore indicates how much revenue Phreesia has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2022
4.01 USD
-2.22 USD
-2.25 USD
Jan 1, 2023
5.08 USD
-3.20 USD
-3.19 USD
Jan 1, 2024
6.12 USD
-2.36 USD
-2.36 USD
Jan 1, 2025
6.79 USD
-0.94 USD
-0.95 USD
Jan 1, 2026
7.63 USD
-0.07 USD
0.04 USD
Jan 1, 2027 (e)
8.54 USD
3.79 USD
0.40 USD
Jan 1, 2028 (e)
8.93 USD
3.96 USD
0.65 USD
Jan 1, 2029 (e)
9.29 USD
4.12 USD
0.77 USD

Phreesia business model & stock analysis

Phreesia Inc is a US-based technology provider for healthcare companies that specializes in automating patient registrations and payments. The company was founded in 2005 by Chaim Indig and Evan Roberts and has since generated revenue of over $100 million. The idea for Phreesia came from Indig and Roberts' frustrating experiences in healthcare company waiting rooms, where patients were burdened with tons of paperwork to fill out. They saw the need to automate processes around patient registrations and payments, to save both patients and healthcare providers time and energy. Phreesia's business model is based on providing software and services that help healthcare companies electronically manage their patient registrations, payments, and communications. The company offers a wide range of products that include patient surveys, insurance information, consent forms, and payment processing. These products are delivered through the cloud-based Phreesia network, which healthcare companies can use to facilitate information exchange between patients and providers. Over the years, Phreesia has developed a variety of divisions, including Phreesia Pulse, Phreesia Payments, and Phreesia Patient Connect. Each of these divisions focuses on different aspects of patient registration and payments, offering specific products and services. Phreesia Pulse is one of Phreesia's key divisions and provides a platform for digital patient surveys. With this platform, healthcare companies can conduct digital surveys using tablets or other mobile devices to gather important information about the patient's medical history, symptoms, and other relevant medical data. Phreesia Payments is another important division of Phreesia, offering a payment processing solution. By integrating payment processing into patient registration and communication, patients can make their payments directly through Phreesia, and healthcare providers can automatically send payment reminders via email or SMS. Phreesia Patient Connect is an innovation that allows patients to connect with their doctor through Phreesia's patient portal. Through the portal, patients can view their medical information, schedule appointments, and communicate with their doctor. Overall, Phreesia has experienced remarkable growth and success in the healthcare market. The company has received numerous awards, including the "Best in KLAS" award in the Patient Access category, as well as being named the "Fastest Growing Company in the Triad" by the Triad Business Journal. Phreesia's business model has fundamentally changed and improved the way healthcare companies manage their patient administration and payments. Not only does Phreesia provide its customers with the necessary tools to automate the registration and payment information of their patients, but it also enables a higher level of patient satisfaction by enhancing information exchange and interaction through digital platforms. As a leading healthcare technology provider, Phreesia will continue to stay true to its mission of developing innovative tools and services that improve the way healthcare companies care for their patients.

Phreesia SWOT Analysis

Strengths

Phreesia Inc has a strong market presence and a solid brand reputation in the healthcare industry. The company offers innovative patient intake solutions that streamline administrative processes, allowing healthcare providers to enhance efficiency and patient experience.

Phreesia's technology is user-friendly and provides comprehensive data analytics, empowering healthcare organizations to make informed decisions. The company has a scalable business model and a flexible platform that can be customized to meet the specific needs of different healthcare settings.

Weaknesses

Phreesia faces intense competition in the healthcare technology sector, which puts pressure on pricing and may impact the company's market share. Additionally, Phreesia's reliance on third-party integrations and partnerships exposes it to potential disruptions or limitations in service provision.

Although Phreesia has built a solid reputation, some potential clients may still be skeptical about adopting new technological solutions, leading to slower adoption rates and longer sales cycles.

Opportunities

The increasing demand for digitization and automation in healthcare presents Phreesia with significant growth opportunities. The company can expand its offerings to include additional modules and features, such as telehealth integrations and remote patient monitoring, to stay ahead of market trends.

Furthermore, Phreesia can explore partnerships with key industry stakeholders, such as electronic medical record (EMR) providers, to integrate its solutions seamlessly into existing healthcare ecosystems. This collaboration can enhance Phreesia's market reach and open doors for cross-selling opportunities.

Threats

One of the potential threats for Phreesia is the presence of well-established competitors with similar products and services. The market entry of new disruptive technologies or the emergence of alternative solutions could also pose a challenge to Phreesia's market position and growth prospects.

Additionally, regulatory changes in the healthcare industry, such as privacy and security requirements, may impose compliance burdens on Phreesia. Non-compliance or data breaches could damage the company's reputation and result in legal and financial consequences.

Phreesia Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Phreesia Employees
Details
Date
Phreesia Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees
Jan 1, 2026
- Employees

Phreesia Segments

Phreesia Revenue by Segment

  • 3 Years

  • 5 Years

  • Max

Subscription and related services
Network solutions
Payment processing fees
Life sciences
Details
Date
Subscription and related services
Network solutions
Payment processing fees
Life sciences
Jan 1, 2020
56.36 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
69.04 M USD
0.00 USD
49.90 M USD
29.74 M USD
Jan 1, 2022
95.51 M USD
0.00 USD
65.20 M USD
52.52 M USD
Jan 1, 2023
128.98 M USD
73.57 M USD
78.37 M USD
0.00 USD
Jan 1, 2024
165.44 M USD
96.25 M USD
94.61 M USD
0.00 USD
Jan 1, 2025
196.51 M USD
121.56 M USD
101.74 M USD
0.00 USD

Phreesia Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Phreesia historical P/E ratio, EBIT multiple, and P/S ratio

Phreesia annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Phreesia shares outstanding

The number of shares of Phreesia was 61.49 M in 2025. This indicates how many shares Phreesia is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
52.61 M Stocks
Jan 1, 2023
55.25 M Stocks
Jan 1, 2024
57.89 M Stocks
Jan 1, 2025
61.49 M Stocks
Jan 1, 2026
62.04 M Stocks
Jan 1, 2027 (e)
62.04 M Stocks
Jan 1, 2028 (e)
62.04 M Stocks
Jan 1, 2029 (e)
62.04 M Stocks

Phreesia Dividend History

7 years of dividend payments

YearAnnual DividendYoY ChangePayments
20140.58USD 3.1%
20130.56USD 75.0%
20122.25USD 0.0%
20112.25USD 0.0%
20102.25USD 0.0%
20092.25USD 118.2%
20081.03USD

Current Phreesia forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.45 %
Buy
95.83 % (23)
Hold
4.17 % (1)
Sell
0.00 % (0)
12M Price Target
28.56
Last Price
10.73
Currency
USD
12M Return Potential
166.17 %
LTM Return
0 %

Phreesia Analyst Rating Actions

DateFirmActionRatingReliability
5/29/2026
Truist Securities
Truist Securities
MaintainedHold
5/28/2026
DA Davidson
DA Davidson
MaintainedBuy
5/28/2026
Citigroup
Citigroup
MaintainedNeutral48
5/28/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
5/20/2026
Wells Fargo
Wells Fargo
DowngradeOverweightEqual Weight56
5/15/2026
Barclays
Barclays
DowngradeOverweightEqual Weight33
4/13/2026
Keybanc
Keybanc
MaintainedOverweight49
4/1/2026
Citizens
Citizens
DowngradeMarket OutperformMarket Perform
3/31/2026
Truist Securities
Truist Securities
DowngradeBuyHold
3/31/2026
Stephens & Co.
Stephens & Co.
MaintainedOverweight

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Phreesia Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/27/20260.01USD-131.43 MUSD-2027 Q1
3/30/20260.07USD-127.99 MUSD-2026 Q4
12/8/20250.00USD-121.25 MUSD-2026 Q3
12/9/2024-0.27USD-107.31 MUSD-2025 Q3
5/29/2024-0.16USD-102.78 MUSD-2025 Q1
3/20/2024-0.35USD-95.87 MUSD-2024 Q4
12/6/2023-0.39USD-94.18 MUSD-2024 Q3
5/31/2023-0.57USD-82.45 MUSD-2024 Q1
3/28/2023-0.59USD-73.27 MUSD-2023 Q4
12/8/2022-0.61USD-71.95 MUSD-2023 Q3

EESG©

Eulerpool ESG Scorecard© for the Phreesia stock

47/100
8
Environment
70
Social
62
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees52
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Phreesia shareholder structure

% Name
9.46224%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.19966%
Capital World Investors
Capital World Investors
2.28349%
Indig (Chaim Edwards)
Indig (Chaim Edwards)
1.02843%
Roberts (Evan)
Roberts (Evan)
0.88021%
Hargreaves Lansdown Fund Managers Ltd.
Hargreaves Lansdown Fund Managers Ltd.
0.83823%
Riverbridge Partners, LLC
Riverbridge Partners, LLC
...

Phreesia Beneficial Ownership Filings (SEC 13D/G)

Free Float
79.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
14.70%
Pale Fire Capital SICAV a.s.
Pale Fire Capital SICAV a.s.
SEC ↗
11.70%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
7.00%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
6.77%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
6.60%
52-0556948
52-0556948
SEC ↗
5.80%
Brown Advisory LLC (BALLC)
Brown Advisory LLC (BALLC)
SEC ↗
5.80%
Brown Advisory Incorporated ("BAI")
Brown Advisory Incorporated ("BAI")
SEC ↗
5.77%
Vanguard Portfolio Management
Vanguard Portfolio Management
SEC ↗
5.60%
13G
13G
SEC ↗
4.70%
Capital International Investors
Capital International Investors
SEC ↗

Phreesia Executives and Management Board

13 members · avg. age 56 · 38 % women

CI

Mr. Chaim Indig (45)

Chief Executive Officer, Director · since 2005

10.51 M USD

Management

BG

Mr. Balaji Gandhi (51)

Chief Financial Officer

4.52 M USD
ER

Mr. Evan Roberts (46)

Chief Operating Officer

4.52 M USD
DL

Mr. David Linetsky (45)

Senior Vice President - Network Solutions

4.49 M USD
AH

Ms. Allison Hoffman (53)

General Counsel, Secretary

2.97 M USD
AV

Ms. Amy VanDuyn (51)

Senior Vice President - Human Resources

Board of Directors

MW

Mr. Michael Weintraub (66)

Independent Chairman of the Board

372,497.00 USD
GM

Ms. Gillian Munson (54)

Independent Director

257,449.00 USD
MS

Dr. Mark Smith (73)

Independent Director

236,664.00 USD
LG

Ms. Lainie Goldstein (57)

Independent Director

234,949.00 USD
RS

Mr. Ramin Sayar (52)

Independent Director

234,164.00 USD
EC

Mr. Edward Cahill (72)

Independent Director

232,449.00 USD

Phreesia Supply Chain

Phreesia Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#NameTrend
1
CompuGroup Medical
Supplier·Customer·Health Care Technology·DE
0.20
0.47
0.29
0.81
0.91
0.55
2
Amazon.com
Supplier·Internet & Direct Marketing Retail·US
-0.65
0.54
0.58
0.76
0.66
0.54
3
Zoom Video Communications A
Customer·Software·US
0.62
0.91
0.88
0.92
0.90
0.43
4
Teladoc Health
Customer·Health Care Technology·US
0.56
0.79
0.94
0.93
0.95
0.36
#NameTrend
1
American Well A
Customer·Health Care Technology·US
0.62
0.66
0.87
0.95
0.89
2
EverCommerce
Customer·Software·US
0.27
0.93
0.86
0.86
3
Cerner
Supplier·Customer·Health Care Technology·US
-0.15
-0.30
-0.78
-0.66
-0.90
-0.42
4
NextGen Healthcare
Supplier·Customer·Health Care Technology·US
-0.61
0.28
0.66
-0.58
-0.85
0.07
5
Allscripts Healthcare Sol
Supplier·Customer·Health Care Technology·US
-0.63
0.85
0.91
-0.28
-0.75
0.08

Frequently asked questions about Phreesia

The business model of Phreesia Inc is centered around providing patient intake and engagement solutions to healthcare organizations. By offering a comprehensive platform, Phreesia streamlines the registration process, collects patient information, verifies insurance eligibility, and facilitates payments. Their services aim to enhance operational efficiency, improve patient experience, and drive revenue growth for clients. Through innovative technology and data analytics, Phreesia empowers healthcare providers to effectively streamline their workflows, optimize patient care, and increase financial performance. The company focuses on delivering value to healthcare organizations by improving the patient journey and enabling a better patient-provider relationship.

Phreesia Inc is primarily active in the healthcare industry.

Some of the main competitors of Phreesia Inc in the market include athenahealth, Cerner Corporation, and athenathealth.

Phreesia Inc is a leading healthcare technology company that specializes in patient intake solutions. Founded in 2005, Phreesia has revolutionized the way healthcare organizations collect patient information, automate workflows, and enhance the patient experience. With their innovative platform, Phreesia has helped thousands of healthcare providers streamline their operations and improve patient engagement. By offering a patient-centric approach, Phreesia has become a trusted partner in the industry, empowering healthcare organizations to deliver high-quality care while reducing administrative burdens. With a strong track record of success and a commitment to innovation, Phreesia continues to be at the forefront of transforming healthcare delivery.

Phreesia Inc has achieved several significant milestones over the years. One of the notable achievements is their successful initial public offering (IPO) in July 2019, which allowed the company to raise substantial capital to fuel their growth. Furthermore, Phreesia has consistently expanded its client base, forging partnerships with numerous leading healthcare organizations across the United States. The company's innovative platform, which streamlines patient intake and payment processes, has garnered recognition and accolades, including being named one of the "50 Most Innovative Companies" by Fast Company in 2020. Phreesia's commitment to driving healthcare efficiency and enhancing patient experiences has positioned them as a prominent player in the industry.

Phreesia Inc is primarily present in the United States.

Phreesia Inc is a healthcare technology company that aims to improve patient experiences and streamline administrative tasks. With a focus on innovation and efficiency, Phreesia provides a comprehensive platform for healthcare providers to manage patient intake, payments, and engagement. The company's corporate philosophy revolves around empowering patients, enhancing clinical decision-making, and improving healthcare outcomes. By leveraging cutting-edge technology and patient-centric solutions, Phreesia strives to revolutionize the healthcare industry. Through its robust platform and commitment to delivering a seamless experience, Phreesia Inc showcases a dedication to advancing patient care and transforming the healthcare landscape.

Analysts currently set an average price target of 29.20 USD for the Phreesia stock (median: 28.56 USD), implying +172.2 % versus the latest price. The consensus is based on 24 analyst ratings.

24 analysts currently rate the Phreesia stock: 23 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Phreesia share trades at 9.32 EUR (10.73 USD).

The Phreesia share (PHR) is listed on 5 stock exchanges, including: NYSE (PHR), Frankfurt (19P.F), München (19P.MU), London (0A23.L), London (0A23.L).

Phreesia Inc is a provider of technology-enabled services that optimize and improve patient traffic in medical practices and healthcare clinics. The company was founded in 2005 and is headquartered in New York City. Phreesia offers a wide range of services, such as patient registration, data entry, insurance verification, bill payment, appointment scheduling, and patient feedback. One of the company's most innovative products is the PhreesiaPad, an electronic tablet that automates paperwork during patient registration in the doctor's office. Phreesia has focused on the outpatient healthcare market, particularly medical practices and health centers, and has garnered numerous large clients, such as NewYork-Presbyterian Hospital and Duke University Medical Center. The company has developed comprehensive software that serves as the interface between physicians, insurance companies, and patients. Phreesia's core business is a subscription model, where customers pay a monthly fee to access the various services offered by the company. The company also partners with insurance companies to directly offer their services to patients. This leads to greater cost transparency and facilitates collaboration between physicians and insurance companies. Phreesia recently invested in telemedicine by partnering with SimplyWell, a digital health coaching company. This partnership allows Phreesia to offer a comprehensive platform for telemedicine and digital health solutions. Overall, Phreesia has developed a business model that enables easier collaboration and improves communication and transparency between physicians, patients, and insurance companies. By providing a comprehensive software solution that takes into account both the workflow in the practice and the requirements and expectations of patients, Phreesia has secured a solid position in the healthcare market.

The revenue of Phreesia is 473.64 M USD. This figure is based on current financial data and reflects the company's business performance.

The profit of Phreesia is 2.31 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Phreesia is currently 288.68. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Phreesia stock.

The price-to-sales ratio (P/S) of Phreesia is currently 1.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Phreesia stock.

The Eulerpool Quality Score for Phreesia is 4/10.

The ISIN of Phreesia is US71944F1066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Phreesia is A2PMY3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Phreesia is PHR. The ticker symbol is used to trade Phreesia shares on the stock exchange.

Phreesia pays a dividend, distributed in the months of , , , .

Phreesia paid dividends every year for the past 0 years.

Phreesia is assigned to the 'Health' sector.

To receive the latest dividend of Phreesia from amounting to 0.58 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Phreesia are distributed in USD.

All fundamentals and in-depth analysis of Phreesia

Our stock analysis for Phreesia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phreesia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.